Bioxytran (BIXT) Interest Expenses (2010 - 2026)
Bioxytran (BIXT) posted Interest Expenses of $35729.0 for Q1 2026, down 2.17% sequentially from $36523.0 in Q4 2025, and up 14.67% YoY from $31157.0 in Q1 2025.
Bioxytran (BIXT) Interest Expenses (2010 - 2026) Analysis & Trends
Bioxytran has reported Interest Expenses for 17 years, with the latest figure at $35729.0 in Q1 2026.
- Quarterly Interest Expenses rose 14.67% year-over-year to $35729.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $138886.0 (down 17.93% YoY) and the FY2025 annual result came in at $3.5 million, up 12.97% from the prior year.
- Interest Expenses eased to $35729.0 in Q1 2026 per BIXT's latest filing, from $36523.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $188630.0 in Q3 2022 and troughed at -$102974.0 in Q4 2023.
- A 5-year average of $46965.9 and a median of $36523.0 in 2025 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2022 and 2023: Interest Expenses jumped 480.85% in 2022, then plunged 124.12% in 2023.
- Over 5 years, Interest Expenses stood at -$45946.0 in 2022, then slumped by 124.12% to -$102974.0 in 2023, then soared by 197.59% to $100497.0 in 2024, then plunged by 63.66% to $36523.0 in 2025, then slipped by 2.17% to $35729.0 in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $35729.0, $36523.0, and $36522.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 82.05 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 20.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 93.62 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -4.89 Mn |
| 10 | Bioxytran | 2.47 Mn | 2.22 Mn | - | 36,126.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35,729.00 |
| Mar 31, 2026 | 35,729.00 |
| Dec 31, 2025 | 36,523.00 |
| Dec 31, 2025 | 36,523.00 |
| Sep 30, 2025 | 36,522.00 |
| Sep 30, 2025 | 36,522.00 |
| Jun 30, 2025 | 30,112.00 |
| Jun 30, 2025 | 30,112.00 |
| Mar 31, 2025 | 31,157.00 |
| Mar 31, 2025 | 31,157.00 |
| Dec 31, 2024 | 100,497.00 |
| Dec 31, 2024 | 100,497.00 |
| Sep 30, 2024 | 17,845.00 |
| Sep 30, 2024 | 17,845.00 |
| Jun 30, 2024 | 19,731.00 |
| Jun 30, 2024 | 19,731.00 |
| Mar 31, 2024 | 163,562.00 |
| Mar 31, 2024 | 163,562.00 |
| Dec 31, 2023 | -102,974.00 |
| Dec 31, 2023 | -102,974.00 |